Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%" is generating significant coverage in the Business category, with 7 articles from 7 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Seeking Alpha, MedWatch, WSJ and BioSpace. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 18d ago.
Quick answers
Why is "Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%" trending?
Because 7 independent news sources published 7 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (7)
- Genmab stock rises on Phase 3 cancer trial data (GMAB:NASDAQ) Seeking Alpha · 20d ago
- Genmab soars as key cancer drug succeeds in late-stage trial MedWatch · 20d ago
- Genmab Shares Soar on Success in Head and Neck Cancer WSJ · 20d ago
- Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout BioSpace · 20d ago
- GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals Yahoo Finance · 20d ago
- Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3 Fierce Biotech · 20d ago
- Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50% Barron's · 20d ago
Topics
Related trends
Stock futures rise slightly as investors eye AI trade, brace for more data and earnings: Live updates
Stock futures rallied as investors bought the dip following a volatile week, though Nvidia shares dropped premarket.
Bloom Energy Stock Rallies as Barclays Turns Bullish on California Power Partnership
Bloom Energy stock rallies following a strategic California power partnership and a bullish shift by Barclays.
Nvidia Stock, Other AI Names Rebound After Sell-Off
Nvidia and other AI-related stocks rebounded Monday after a sell-off, with investors focused on upcoming earnings and data-center demand signals.
Zelda 40th Anniversary Switch 2 Stock: Restock Status and Where to Buy In-Store and Online
The Legend of Zelda 40th Anniversary Edition Switch 2 pushed U.S. hardware dollar sales to their highest weekly total of 2026 in the week ending October 31, according to Circana analyst Mat Piscatella.
Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly
Eli Lilly has struck a deal allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on its platform.
Stock futures fall after Nasdaq correction; Japan's Nikkei 225 enters bear market: Live updates
Global markets reel as tech stocks plunge and Wall Street loses trillions following a historic sell-off.